ogy and its application to cancer has shifted our understanding of the disease and the basis of its treat ent u ors for erly categori ed as a single entity on the basis of microscopic appearance are now known to be diverse in their molecular characteristics. Despite their clonal interrelationships, tumors within an individual have been shown to be heterogeneous in dif ferent sites and in large masses in the same site.
nd the presence of particular genetic lesions has been found sufficient to dictate the choice of therapy for a number of tumor types includ ing subsets of lung cancers, melanomas, thyroid cancers, and others.
he application of these sophisticated ana lytic techni ues to arrive at a therapy for a par ticular cancer has been called personali ed oncology." However, we should not regard the creation of a particular treatment plan for an individual patient as a new idea. he image of oncology as applying routine treatment "reci pes" to patients with particular types of cancer is not a full picture of the discipline. Indeed, the notion of tailoring the treatment to a patient's particular tumor is as old as oncology itself.
In the late s, once it became clear that certain drugs could cause regressions in patients with cancer but were also to ic to nor mal tissues, it became necessary to develop an approach to cancer treatment that gave the patient the best chance of response with the lowest risk of life threatening to icity. ne of the pioneers in medical oncology and an origi nal founder of the merican ociety of linical ncology, ane ooke right, .D., who died on ebruary , at age , brought passion and persistence to her work as a physician and researcher. he rare responses that were seen with chemotherapy encouraged her to try to e plain why some patients responded and oth ers did not.
right analy ed the activity of anticancer agents by comparing tissue culture response to patient response. Dr. right put fresh tumor biopsy material into tissue culture and assessed whether an in vitro response to a particular agent predicted a clinical response in the patient to the same agent. In a ew ngland ournal of edicine paper published in , she laid the groundwork for tailoring treatment to a particu lar patient's tumor by reporting the correlation between the in vitro and in vivo response.
ools to refine the choice of personali ed therapy have continued to evolve. Despite the promise, no method of tailoring treatment to the particular drug sensitivities of a tumor in an individual patient based on pretreatment test ing have become a standard for cancer manage ment. Instead, the focus has been on identifying the presence of particular genetic lesions that predict for response to particular drugs. umors with mutations in driver kinases are more likely to respond to kinase inhibitors. umors with defects in the D repair machinery are more likely to respond to a D damaging agent plus a poly D ribose polymerase inhibitor. umors that e press a particular tar get antigen are more likely to respond to anti bodies, immunoto ins, or engineered cells that recogni e that antigen. s we learn more about molecular mechanisms of resistance, it seems that combining inhibitors of se uential steps in a signaling pathway or blocking two pathways may improve response and decrease emer gence of resistance.
early all the work to personali e can cer treatments has been focused on defining characteristics of the tumor that predict for response to a particular treatment. his focus is too limited. reatment plans must also take into consideration certain features of the patient.
harmacogenomics may influence the metabo lism of a drug with either enhanced or inhibited activity for e ample, irinotecan is unsafe to give patients with Gilbert's syndrome, an otherwise completely benign defect in uridine diphos phate glucuronyl transferase G , because the missing en yme is crucial to deto ification of the drug. ytochrome en yme D poly morphisms can affect the efficacy of narcotic analgesia.
lpha ed ress Longo TheOncologist.com lpha ed ress www.TheOncologist.com microscopy, then improved cytogenetics, then monoclonal antibody facilitated improvement in definition of cell surface characteristics, and most recently, sophisticated analyses of genes and their products, we now recogni e that there are at least kinds of lymphomas. nd as a conse uence of new therapeutic agents, particular regimens have been designed that are highly effective in patients who have the same molec ularly defined disease types. The implication of "personali ed medicine" is a "one si e fits one" paradigm. e are and should be a long way from that e treme.
e still treat entities that we recogni e as being of a par ticular type with a treatment that has been shown to work in tumors of that type, as we should. The notion that this is a paradigm shift reflects a failure to understand oncology and the principles upon which the field was founded. The philosophy is the same the knowledge base and the thera peutic tools are changing and we are ust getting better at e ecuting the strategy. olecular nosology of cancer is not personali ed oncology. ersonali ed oncology is much big ger than that.
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unctional assessment is also a component of person ali ed cancer care.
year old patient with several seri ous comorbidities and arnofsky performance status of is unlikely to tolerate the same therapy as the year old healthy athlete with performance status of . cellent oncology care has always been personali ed, not only taking into account important features of the tumor and the physiol ogy of the host, but also the holistic idea of the emotional and spiritual state and the goals of the patient.
The progress that is taking place based on e ploitation of new knowledge of what makes cancers progress is leading to interventions with unprecedented levels of antitumor activ ity and resulting in a prolongation of survival of patients with tumor types that would have been rapidly fatal a few years ago. Yet our advances in the molecular nosology of cancer should not be thought of as a revolutionary change in the philosophy of the field. The implication that oncology care was "one si e fits all" is incorrect. Oncologists have always sought to create treatment that was well suited to the individual patient. There was a time when the state of the art in pathology was capable of recogni ing three types of lymphoma. Tumors derived from T cells and tumors derived from cells were treated similarly.
s a conse uence of advances in technology, first improved E N lease see the accompanying article on pages of this issue.
